Xencor Inc. (XNCR) is a cutting-edge biopharmaceutical firm specializing in the discovery and development of engineered monoclonal antibodies for the treatment of cancer, autoimmune disorders, asthma, and numerous other diseases. Established in 1997 and headquartered in Monrovia, California, Xencor Inc. harnesses the potential of technology to create new standards in biotech and healthcare.
Xencor Inc. primarily focuses on XmAb® technology, its proprietary antibody engineering platform. This pioneering technology explores the unique biological properties of antibodies and allows the modification of protein structures for enhanced performance. Xencor's plug-and-play technology significantly helps to diversify the potential applications and allows the creation of proprietary therapeutic antibodies with improved pharmacologic properties.
Xencor Inc. has an impressive portfolio that consists of more than a dozen internally-developed candidates and partnerships with leading global pharmaceutical companies. Its notable alliances include collaborations with Alexion, Novartis, Genentech, Janssen, and Boehringer Ingelheim. These strategic collaborations not only provide revenues through milestone payments but also allow Xencor to access substantial R&D resources and expand its therapeutic horizons.
Concentrating on the development of XmAb bispecific technology, Xencor restructures an antibody's Fc domain that helps engage two different targets simultaneously, providing groundbreaking strategies for fighting diseases. Xencor's lead product candidates utilizing this technology include XmAb5871 and XmAb7195; both have showcased potential results in clinical studies.
Despite having multiple experimental candidates in their pipeline, Xencor retains its global commercial rights, granting the company full control over its promising future products. Xencor is also involved in several early-stage therapies, co-developed through partnering strategies.
The company’s innovative and novel approach has made it a pioneer in the antibody engineering space, and the XmAB technology holds potential in ushering in a new era of antibody therapeutics. Their work has the potential to provide game-changing therapies for patients suffering from multiple severe and life-threatening diseases.
In the rapidly evolving biopharmaceutical landscape, Xencor Inc. stands out with its robust pipeline and proactive engagements in research collaborations. By focusing intently on improving and optimizing the performance of antibodies to treat diverse health conditions, the firm is harnessing and advancing biotechnology to realize its vision of transforming lives through better medicine.
In conclusion, Xencor Inc. (XNCR) is a dynamic and innovative player in the biopharmaceutical industry, keenly focused on pushing boundaries, revolutionizing treatments, and reinventing the future of healthcare. Blending scientific creativity, technological acumen, and industrial collaborations, Xencor is steering the sector towards promising horizons of patient care and therapeutic interventions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $40 from $29, while maintaining a Buy rating. This increase follows XmAb819's compelling ESMO showing and investor call, with the analyst noting a 45.5% cORR and 82% 6-month PFS in ccRCC patients. The analyst believes XmAb819 is a credible novel therapy with manageable safety, supporting potential accelerated approval discussions in 1H27 and raising peak sales estimates to $1.1 billion.
Xencor announced updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, showing a 45.5% objective response rate at the 400 microgram-per-kilogram dose. The company has selected this dose for planned Phase 3 development and intends to discuss accelerated approval and a randomized study with the FDA in the first half of 2027. Safety concerns like cytokine release syndrome and rash were manageable, largely low-grade, and self-limited.
Xencor Inc. (NASDAQ: XNCR) shares are trading higher after the company presented updated Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) at the ESMO Congress 2026. The drug demonstrated robust response rates and favorable safety, leading William Blair analysts to praise its "unprecedented profile." Xencor plans to advance XmAb819 into late-stage testing and explore accelerated approval pathways with the FDA.
Xencor (NASDAQ: XNCR) announced Phase 1 results showing a 45.5% confirmed tumor shrinkage rate in 11 evaluable kidney-cancer patients at a selected dose of 400 micrograms per kilogram for its experimental antibody, XmAb819. The company plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027 and initiate a global randomized study next year. Despite severe treatment-related adverse events in 72.1% of patients across expansion cohorts, the results support dose selection for future development.
Wedbush has reiterated its "Outperform" rating for Xencor (NASDAQ:XNCR), setting a price target of $30.00, which implies a 19.24% upside from its previous close. This positive sentiment is shared by other analysts, resulting in a consensus "Moderate Buy" rating and an average price target of $34.00. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting a $0.29-per-share loss against a projected $0.80 loss, and revenues of $51.22 million.
Xencor (XNCR) is gaining investor attention following plans for an October 26 webcast to discuss Phase 1 data for its XmAb819 kidney cancer program and outline a 2027 registration study. The stock has seen significant rallies recently, suggesting strong momentum around its pipeline. While Simply Wall St's narrative pegs Xencor as 21% undervalued, potential risks like underwhelming data or increased competition could impact its future.